Skip to content

Over 65 Abstracts Featuring clonoSEQ® MRD Testing to be Presented at the 66th ASH Annual Meeting

Investors
Join Our Team

- About
- Drug Discovery
- About
- Clinical Portfolio & Pipeline
- Publications
- Clinical Diagnostics
- clonoSEQ
- Biopharma Solutions
- Biopharma Services
- Blog
- Media
  - Press Releases
  - Media Resources
  - Events
  - Conferences & Events
- Publications
  - Research Publications
  - Credentials
  - Licenses and Accreditation
- Medical
- About Us
- Careers
  - Career Listings
  - Connect
  - Contact
  - Investors
  - Investor Relations
  - Newsroom

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naive, TP53-Mutant Mantle Cell Lymphoma

Read the latest from Adaptive

Immune Medicine

Immune Medicine Platform
The Adaptive Immune System
TCR Antigen Map
Publications

Pharma Services

Research & Development Applications
Adaptive Immunosequencing

Drug Discovery

TCR Therapeutics
Antibody Therapeutics
Target Discovery

MRD

Clinical Portfolio & Pipeline
Publications

Clinical Diagnostics

clonoSEQ

News & Events

Press Releases
Media Resources
Blog
Conferences & Events

Our Science

Publications

Research Publications

Credentials

Licenses & Accreditation

Medical

Medical Affairs
Medical Information
Data & Congress

About Us

Who We Are
Our Story
Innovation Timeline
Leadership
Investor Relations
Newsroom
Contact
Careers

Diagnostics (888) 552-8988 | Corporate (206) 659-0067

View our facebook' View our youtube' View our twitter' View our instagram' View our linkedin'

Sitemap
Privacy Policy
Cookie Policy
Notice at Collection
Do Not Sell or Share My Info
Terms of Service
Code of Conduct

© Adaptive Biotechnologies. All Rights Reserved.